What's in Mirum Pharmaceuticals, Inc.'s pipeline?

Mirum Pharmaceuticals, Inc. has 7 drugs in our index: 3 marketed, 0 filed, 2 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with Mirum Pharmaceuticals, Inc.'s portfolio?

Top competitors by shared drug class: Lars Kristian Munck.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mirum-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Mirum Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mirum Pharmaceuticals, Inc. pipeline: 3 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 2 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Livmarli Oral Product	Livmarli Oral Product	marketed
Cholbam	Cholbam	marketed		G-protein coupled bile acid receptor 1, Bile acid receptor	Metabolic
Livmarli	Livmarli	marketed		Ileal sodium/bile acid cotransporter	Other
CDCA Weight-Based Dose TID	CDCA Weight-Based Dose TID	phase 3	Bile acid receptor agonist	FXR (farnesoid X receptor), TGR5	Hepatology / Gastroenterology
Cholic Acids	Cholic Acids	phase 3	Bile acid replacement therapy	Farnesoid X receptor (FXR) and TGR5 signaling pathways	Gastroenterology / Metabolic Disorders

Therapeutic area mix

Gastroenterology / Metabolic Disorders · 1
Hepatology / Gastroenterology · 1
Metabolic · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Lars Kristian Munck · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Mirum Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Mirum Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mirum-pharmaceuticals-inc. Accessed 2026-05-16.